In You et al.’s study of anti-MDA5 + DM patients, they discovered that anti-Ro-52 antibody positivity as well as moderate to high anti-MDA5 antibody titers, among others, were independent risk factors for RP-ILD, and RP-ILD itself was identified as an independent risk factor for mortality [56]. This evidence concerns the gene TRIM21 and dermatomyositis.